Weiterführende Literatur

Adam RA et al. Malignant ascites: past, present, and future. J Am Coll Surg 2004; 198 (6):999-1011

Adebayo D et al. P0187 : A Randomized controlled trial comparing the alfapump© with paracentesis in patients with refractory ascites: Clinical and pathophysiological effects on cardiac, haemodynamic, inflammatory, renal and nutritional parameters. J of Hepatology 2015, 62 (2): S374

Becker G et al. Maligner Aszites. Pathogenese, Diagnose und Möglichkeiten der Symptomkontrolle. Z Palliativmedizin 2009; 10:143-153

Böcking A. et al. Treffsicherheit der Ergusszytologie samt adjuvanten Untersuchungsmethoden. Deutsches Ärzteblatt 6-10-2000; 97:2626-2630

Lee CW et al. A survey of practice in management of malignant ascites. J Pain Symptom Manage. 1998; 16(2): 96-101

Rosenberg SM. Palliation of malignant ascites. Gastroenterol Clin North Am 2006; 35:189-99

Seiden MV et al. A pivotal phase III trial to evaluate the efficacy and safety of adjuvant treatment with R1549 (yttrium-90-labeled HMFG1 murine monoclonal antibody) in epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 2004; 23:451s (abstr 5008)

Smith EM et al. The current and future management of malignant ascites. Clin Oncol (R Coll Radiol) 2003; 15:59-72

Tamsma J. The pathogenesis of malignant ascites. Cancer Treat Res 2007; 134:109–118

Wiest R , Schölmerich J. Diagnostik und Therapie des Aszites. Deutsches Ärzteblatt 2006; 28-29: A1972-A1980